Head-to-head evidence
VENT-02 vs VTX3232
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: NLRP3 · full Parkinson's Disease pipeline
VENT-02
Developed by Ventus Therapeutics U.S., Inc.
NCT06822517 · Phase 1/2 · terminated
This is a small but properly randomized, fully blinded, placebo-controlled study; results are not yet posted, and its primary focus is safety rather than a disease outcome, so it supports a moderate rating pending data.
VTX3232
Developed by Zomagen Biosciences and partners
NCT06556173 · Phase 2 · completed
The study was a small, single-arm, open-label trial with no placebo or active comparator and no randomization. Its primary endpoint was adverse-event incidence. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: VENT-02's landscape · VTX3232's landscape